Ida Monrad

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.

Søren E. Jespersen, H. Ngo, J. Gunst, 2021, EClinicalMedicine.

The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection.

T. O'Brien, J. Gunst, M. Tolstrup, 2021, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Redirector of Vaccine-induced Effector Responses (RoVER) for specific killing of cellular targets

J. Gunst, M. Tolstrup, R. Hartmann, 2023, EBioMedicine.

SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity

J. Gunst, M. Tolstrup, C. Erikstrup, 2020, bioRxiv.

PD-1 Expression in Pre-Treatment Follicular Lymphoma Predicts the Risk of Subsequent High-Grade Transformation

S. Hamilton-Dutoit, B. Honoré, F. d'Amore, 2021, OncoTargets and therapy.

OTT_A_289337 481..489

B. Honoré, F. d'Amore, T. Plesner, 2021 .

Soluble programmed cell death protein 1 (sPD‐1) and the soluble programmed cell death ligands 1 and 2 (sPD‐L1 and sPD‐L2) in lymphoid malignancies

P. Kamper, F. d'Amore, M. Bjerre, 2021, European journal of haematology.

SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses

J. Gunst, M. Tolstrup, L. Østergaard, 2021, EBioMedicine.

CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy

M. Tolstrup, L. Østergaard, O. Søgaard, 2022, Frontiers in Cellular and Infection Microbiology.

Glycolytic biomarkers predict transformation in patients with follicular lymphoma

S. Hamilton-Dutoit, B. Honoré, F. d'Amore, 2020, PloS one.